JP2007512376A - 肥満症の予防及び治療用ビタミンｄ類似体 - Google Patents

肥満症の予防及び治療用ビタミンｄ類似体 Download PDF

Info

Publication number
JP2007512376A
JP2007512376A JP2006541728A JP2006541728A JP2007512376A JP 2007512376 A JP2007512376 A JP 2007512376A JP 2006541728 A JP2006541728 A JP 2006541728A JP 2006541728 A JP2006541728 A JP 2006541728A JP 2007512376 A JP2007512376 A JP 2007512376A
Authority
JP
Japan
Prior art keywords
analog
carbon atoms
linear
branched
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006541728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512376A5 (https=
Inventor
デイム マーガレット クラゲット
ヘクター エフ デルーカ
ジェイミー エム アーレンズ
ジェイムズ エム ンタンビ
ブライアン トムソン
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2007512376A publication Critical patent/JP2007512376A/ja
Publication of JP2007512376A5 publication Critical patent/JP2007512376A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006541728A 2003-11-25 2004-11-24 肥満症の予防及び治療用ビタミンｄ類似体 Abandoned JP2007512376A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52481303P 2003-11-25 2003-11-25
US52479803P 2003-11-25 2003-11-25
PCT/US2004/039625 WO2005051323A2 (en) 2003-11-25 2004-11-24 Vitamin d analogs for obesity prevention and treatment

Publications (2)

Publication Number Publication Date
JP2007512376A true JP2007512376A (ja) 2007-05-17
JP2007512376A5 JP2007512376A5 (https=) 2008-01-24

Family

ID=41057499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541728A Abandoned JP2007512376A (ja) 2003-11-25 2004-11-24 肥満症の予防及び治療用ビタミンｄ類似体

Country Status (7)

Country Link
US (1) US8188064B2 (https=)
EP (1) EP1689412A4 (https=)
JP (1) JP2007512376A (https=)
AU (1) AU2004293092A1 (https=)
CA (1) CA2544502A1 (https=)
MX (1) MXPA06005887A (https=)
WO (1) WO2005051323A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532540A (ja) * 2004-04-09 2007-11-15 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物
JP2008520710A (ja) * 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９，２１−ジノル−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
JP2008520704A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
JP2008520691A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−メチレン−１９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３およびその使用
JP2011527699A (ja) * 2008-07-10 2011-11-04 ウィスコンシン アラムナイ リサーチ ファンデーション ２−メチレン−１９，２６−ジノル−（２０ｓ，２２ｅ，２５ｒ）−ビタミンｄ類似物質
JP2011527695A (ja) * 2008-07-10 2011-11-04 ウィスコンシン アラムナイ リサーチ ファンデーション ２−メチレン−１９，２６−ジノル−（２０ｒ，２２ｅ，２５ｒ）−ビタミンｄ類似物質
JP2016509601A (ja) * 2013-01-23 2016-03-31 ウイスコンシン アラムニ リサーチ ファンデーション （２２Ｅ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３類似体
JP2018521010A (ja) * 2015-05-26 2018-08-02 ウイスコンシン アラムニ リサーチ ファンデーション １α，２５−ジヒドロキシ−２４，２４−ジフルオロ−１９−ノルビタミンＤ３類似体およびそれらの薬学的使用法

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
AU2004266706B2 (en) * 2003-08-20 2009-07-30 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D2 compounds
US8404667B2 (en) 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
CA2588399A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
US8399438B2 (en) 2004-11-22 2013-03-19 Wisconsin Alumni Research Foundation 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses
US8222235B2 (en) 2004-11-22 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol
EP1828115A4 (en) * 2004-11-22 2010-05-05 Wisconsin Alumni Res Found 2-METHYLENE-19-NOR (20S) -1ALPHA-HYDROXYTRISHOMOPREGNACALCIFEROL
JP5043674B2 (ja) * 2004-11-22 2012-10-10 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−メチレン−１８，１９−ジノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用
AU2005309789A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses
DK1848442T3 (da) * 2005-02-11 2012-05-29 Wisconsin Alumni Res Found 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2
US8114393B2 (en) * 2005-09-14 2012-02-14 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
CA2623481A1 (en) * 2005-09-22 2007-04-05 Wisconsin Alumni Research Foundation 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3
US7803789B2 (en) 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
NZ571896A (en) 2006-04-05 2011-09-30 Wisconsin Alumni Res Found 1-Alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and use thereof
WO2008035207A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
NZ570712A (en) * 2006-04-06 2011-11-25 Wisconsin Alumni Res Found 2-methylene-1alpha-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof
NZ570711A (en) 2006-04-06 2012-10-26 Wisconsin Alumni Res Found 2-Substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
MX2008012912A (es) * 2006-04-06 2008-11-26 Wisconsin Alumni Res Found Analogos de 2-metilen-1a,25-dihidroxi-19,21-dinorvitamina d3 y sus usos.
EP2021321B1 (en) 2006-04-06 2012-06-20 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
EP2001860A2 (en) * 2006-04-06 2008-12-17 Wisconsin Alumni Research Foundation 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring
EP2004597B1 (en) * 2006-04-10 2011-01-26 Wisconsin Alumni Research Foundation 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds with a 1,1-dimethylpropyl side chain
EP2069296B1 (en) 2006-09-28 2012-04-04 Wisconsin Alumni Research Foundation 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs
AU2007300214A1 (en) * 2006-09-28 2008-04-03 Wisconsin Alumni Research Foundation 2-methylene-(20R,25S)-19,27-dinor-(22E)-vitamin D analogs
ATE552239T1 (de) * 2007-12-28 2012-04-15 Wisconsin Alumni Res Found 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga
WO2009086436A1 (en) * 2007-12-28 2009-07-09 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
AU2009221717A1 (en) * 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of A 19-nor containing vitamin D compound
US7888339B2 (en) 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
US7893043B2 (en) 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8222236B2 (en) 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
MX2012005936A (es) * 2009-11-30 2012-09-07 Wisconsin Alumni Res Found 2-metilen-19,26-nor-(20s)-1a-hidroxivitamina d3.
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
CA2793727C (en) * 2010-03-23 2017-01-03 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1.alpha.,25-dihydroxyvitamin d3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US8420839B1 (en) * 2011-10-05 2013-04-16 Wisconsin Alumni Research Foundation Crystallization of 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol
CN104211579B (zh) * 2014-09-04 2016-01-06 上海皓元生物医药科技有限公司 一种用于制备维生素d及其类似物的中间体化合物ii的方法
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
CN104447211A (zh) * 2014-12-12 2015-03-25 重庆华邦制药有限公司 维生素d类药物的中间体化合物及制备方法
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
EP0619306B1 (en) 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
US5552392A (en) 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6392071B1 (en) 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
ATE344039T1 (de) 1999-04-01 2006-11-15 Univ Johns Hopkins Nicht-calcemische, transkriptionell-aktive, schwefelhaltige analoga von 1-alpha, 25- dihydroxyvitamin d3 mit antiproliferativer wirkung
US6384087B1 (en) * 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
US7704979B2 (en) * 2000-09-01 2010-04-27 The University Of Tennessee Research Foundation Materials and methods for the treatment or prevention of obesity
NZ524657A (en) 2000-09-08 2004-12-24 Wisconsin Alumni Res Found 1 alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
HK1079766B (zh) 2002-03-29 2007-05-25 威斯康星校友研究基金会 合成1α-羟基-2-亚甲基-19-去甲-高孕钙化醇的方法
AU2004266706B2 (en) 2003-08-20 2009-07-30 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D2 compounds
WO2005027929A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
KR20060058133A (ko) 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 ｄ 유도체 및 부갑상선호르몬의 조합을 포함하는 약학 조성물 및 방법
BRPI0414448A (pt) 2003-09-19 2006-11-14 Pfizer Prod Inc composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio
CA2588399A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
AU2005309789A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532540A (ja) * 2004-04-09 2007-11-15 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物
JP2008520710A (ja) * 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９，２１−ジノル−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
JP2008520704A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
JP2008520690A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｅ）−デヒドロビタミンｄ類似体およびそれらの使用
JP2008520691A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−メチレン−１９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３およびその使用
JP2011527699A (ja) * 2008-07-10 2011-11-04 ウィスコンシン アラムナイ リサーチ ファンデーション ２−メチレン−１９，２６−ジノル−（２０ｓ，２２ｅ，２５ｒ）−ビタミンｄ類似物質
JP2011527695A (ja) * 2008-07-10 2011-11-04 ウィスコンシン アラムナイ リサーチ ファンデーション ２−メチレン−１９，２６−ジノル−（２０ｒ，２２ｅ，２５ｒ）−ビタミンｄ類似物質
JP2016509601A (ja) * 2013-01-23 2016-03-31 ウイスコンシン アラムニ リサーチ ファンデーション （２２Ｅ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３類似体
JP2018521010A (ja) * 2015-05-26 2018-08-02 ウイスコンシン アラムニ リサーチ ファンデーション １α，２５−ジヒドロキシ−２４，２４−ジフルオロ−１９−ノルビタミンＤ３類似体およびそれらの薬学的使用法

Also Published As

Publication number Publication date
EP1689412A2 (en) 2006-08-16
WO2005051323A2 (en) 2005-06-09
CA2544502A1 (en) 2005-06-09
AU2004293092A1 (en) 2005-06-09
EP1689412A4 (en) 2009-03-11
US8188064B2 (en) 2012-05-29
US20050119242A1 (en) 2005-06-02
WO2005051323A3 (en) 2005-07-07
MXPA06005887A (es) 2006-06-27

Similar Documents

Publication Publication Date Title
JP2007512376A (ja) 肥満症の予防及び治療用ビタミンｄ類似体
KR100345820B1 (ko) 2-알킬-19-노르-비타민 ｄ 화합물
CN100438877C (zh) (20S)－1α－羟基－2α－甲基和2β－甲基－19－去甲－维生素D3及它们的用途
JP4022071B2 (ja) ２−アルキリデン−１９−ノル−ビタミンｄ化合物及びその治療的使用
CA2637302C (en) Vitamin d analog-rak, methods and uses thereof
JP2004501114A (ja) ２−エチル及び２−エチリデン−１９−ノル−ビタミンｄ化合物
JP2006117680A (ja) ２−アルキリデン−１９−ノル−ビタミンｄ化合物
WO2007092720A2 (en) Vitamin d analog: nel, methods and uses thereof
JP2004500414A (ja) ２６，２７−同族体化−２０−エピ−２−アルキル−１９−ノルビタミンｄ化合物
AU2007234717A1 (en) 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
US20070213546A1 (en) 2-Propylidene-19-nor-vitamin D compounds
JP2011507966A (ja) ２−メチレン−２０−メチル−１９，２４，２５，２６，２７−ペンタノル−ビタミンｄ類縁体
JP2008542201A (ja) １９，２６，２７−トリノル−１α，２５−ジヒドロキシビタミンＤ３化合物
JP5036566B2 (ja) ２−メチレン−１９−ノル−（２０Ｓ−２４Ｓ）−１α，２５−ジヒドロキシビタミン−Ｄ２
US8404666B2 (en) 2-substituted-1α,25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
JP2008520709A (ja) ２−メチレン−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−トリスホモプレグナカルシフェロール
JP4988551B2 (ja) ２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物
JP5043674B2 (ja) ２−メチレン−１８，１９−ジノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用
JP5036565B2 (ja) ２−メチレン−１９−ノル−（２０Ｓ−２４エピ）−１α，２５−ジヒドロキシビタミン−Ｄ２
JP2008520708A (ja) ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
JP2008538214A (ja) ２−メチレン−１９−ノル−（２３Ｓ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトンおよび２−メチレン−１９−ノル−（２３Ｒ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトン
AU2007349772A1 (en) 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof
JP2021167319A (ja) カルシトリオールの２−メチレン類似体および関連化合物の合成および生物活性
HK1086817B (en) 2- propylidene-19-nor-vitamin d compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071126

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20100402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100402